Canada markets closed

Affimed N.V. (AFMD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.1900-0.5200 (-11.04%)
At close: 04:00PM EDT
4.0000 -0.19 (-4.53%)
After hours: 07:30PM EDT

Affimed N.V.

Gottlieb-Daimler-Straße 2
Mannheim 68165
Germany
49 621 560030
https://www.affimed.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees76

Key Executives

NameTitlePayExercisedYear Born
Dr. Andreas Harstrick M.D.Interim CEO, Chief Medical Officer & Member of Management Board488.34kN/A1961
Dr. Wolfgang Fischer Ph.D.MD, COO & Member of Management Board590.35kN/A1964
Ms. Denise MuellerChief Business Officer & Member of Management Board528.49kN/A1970
Prof. Melvyn LittleFounder & ConsultantN/AN/AN/A
Mr. Michael WolfHead of Finance & AdministrationN/AN/A1967
Mr. Alexander FudukidisHead of Investor Relations & Director of Investor RelationsN/AN/AN/A
Mary Beth SandinVice President of Marketing & CommunicationsN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

Corporate Governance

Affimed N.V.’s ISS Governance QualityScore as of May 1, 2024 is 6. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 3; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.